7 of the 45 female-biased drug-adverse event pairs with SBAE-associated drugs targeting FCGR2B had female-biased adverse events related to general disorders and administration site conditions, and six female-biased drug-adverse event pairs were infections and infestations (Supplemental Fig. 12). Here, FCGR2B is linked to infection.